Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MF With Splenomegaly”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Early research (Phase 1)Looking for participantsNCT07802405
What this trial is testing

Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
MF With Splenomegaly
Henan Cancer Hospital 20
Testing effectiveness (Phase 2)Study completedNCT03222609
What this trial is testing

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Who this might be right for
Myelofibrosis (MF)
AbbVie 191
Testing effectiveness (Phase 2)Ended earlyNCT02730884
What this trial is testing

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Who this might be right for
LeukemiaMyelofibrosisAnemia+1 more
M.D. Anderson Cancer Center 3
Early research (Phase 1)Study completedNCT03895112
What this trial is testing

MPN-RC 118 AVID200 in Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more
John Mascarenhas 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT06909136
What this trial is testing

Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly
Suzhou Junjing BioSciences Co., Ltd. 33